文献速递角膜与眼表疾病

真菌性角膜炎基质内注射伏立康唑的随机临床试验

Mycotic Antimicrobial Localized Injection: A Randomized Clinical Trial Evaluating Intrastromal Injection of Voriconazole.
PubMed 文献 · Ophthalmology · 2019-03-20

该随机对照试验纳入70例涂片阳性丝状真菌性角膜溃疡患者,比较局部 natamycin 联合基质内伏立康唑注射与单用 natamycin 的疗效。结果显示联合 ISV 注射在3天和7天微生物学治愈、视力及浸润/瘢痕大小方面均无显著获益,且穿孔风险有升高趋势但无统计学意义。结论提示在丝状真菌性角膜溃疡的初始治疗中加用 ISV 注射似乎无益。

要点

  • 联合 ISV 注射未提高3天或7天培养转阴率。
  • 联合 ISV 注射未改善3个月视力或浸润/瘢痕大小。
  • ISV 注射组穿孔风险有升高趋势但无统计学意义。

核心结论

  • 在丝状真菌性角膜溃疡的初始治疗中,局部 natamycin 加用基质内伏立康唑注射似乎无获益。
  • 研究一致提示伏立康唑在丝状真菌性角膜溃疡治疗中作用有限。

研究设计与样本

  • 采用结果评估者设盲的随机对照临床试验设计。
  • 在印度 Pondicherry 的 Aravind 眼科医院筛选151例涂片阳性角膜溃疡患者,最终纳入70例。

主要发现

  • 基线培养显示镰刀菌19例(27%)、曲霉菌17例(24%)、其他丝状真菌19例(27%)、阴性13例(19%)。
  • ISV 组3天培养阳性的比值比为1.82(95%CI 0.65-5.23;P=0.26),7天培养阳性的比值比为1.98(95%CI 0.69-5.91;P=0.20)。
  • 3个月时 ISV 组视力下降0.5 logMAR行(约0.5 Snellen行;95%CI -2.6至3.6行;P=0.75),浸润或瘢痕大小差0.55 mm(95%CI -0.13至1.25;P=0.11)。
  • ISV 组穿孔风险比为2.85(95%CI 0.76-10.75;P=0.12),治疗性穿透性角膜移植风险比为0.95(95%CI 0.44-2.04;P=0.90)。

关键数值与推荐

  • 主要结局为3天重复培养的微生物学治愈。
  • 次要结局包括7天重复培养微生物学治愈、3周和3个月最佳矫正视力、浸润或瘢痕大小、穿孔率、治疗性穿透性角膜移植及其他不良事件。

临床怎么用

  • 对于涂片阳性的丝状真菌性角膜溃疡,不推荐常规加用基质内伏立康唑注射作为初始辅助治疗。

局限性

  • 研究仅纳入涂片阳性且伴中度视力丧失的患者,结论外推需谨慎。
  • 部分结局指标的置信区间较宽,提示样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine if there is a benefit to adjuvant intrastromal voriconazole (ISV) injections for primary treatment of filamentous fungal keratitis. DESIGN: Outcome-masked, randomized controlled clinical trial. PARTICIPANTS: Patients with moderate vision loss resulting from a smear-positive fungal ulcer. METHODS: Study eyes were randomized to topical natamycin plus ISV injection versus topical natamycin alone. MAIN OUTCOME MEASURES: The primary outcome of the trial was microbiological cure on 3-day repeat culture analysis. Secondary outcomes included microbiological cure on 7-day repeat culture analysis; 3-week and 3-month best spectacle-corrected visual acuity; infiltrate or scar size or both; rate of perforation; therapeutic penetrating keratoplasty (TPK); and other adverse events. RESULTS: A total of 151 patients with smear-positive ulcers were screened and 70 were enrolled at Aravind Eye Hospital, Pondicherry, India. Baseline cultures grew Fusarium in 19 samples (27%), Aspergillus in 17 samples (24%), and other filamentous fungi in 19 samples (27%) and showed negative results in 13 samples (19%). Those randomized to ISV injection had 1.82 times the odds of 3-day culture positivity after controlling for baseline culture status (95% confidence interval [CI], 0.65-5.23; P = 0.26, bias-corrected logistic regression) and 1.98 times the odds of positive 7-day culture results, after controlling for baseline culture status (95% CI, 0.69-5.91; P = 0.20, bias-corrected logistic regression). Those randomized to ISV injection showed 0.5 logMAR lines (approximately 0.5 Snellen lines) of decreased visual acuity (95% CI, -2.6 to 3.6 lines; P = 0.75) and 0.55 mm worse infiltrate or scar size or both at 3 months after controlling for baseline values (95% CI, -0.13 to 1.25; P = 0.11). Intrastromal voriconazole injections showed a 2.85-fold increased hazard of perforation after controlling for baseline infiltrate depth (95% CI, 0.76-10.75; P = 0.12) but no difference in the rate of TPK (hazard ratio, 0.95; 95% CI, 0.44-2.04; P = 0.90). CONCLUSIONS: There seems to be no benefit to adding ISV injections to topical natamycin in the primary treatment of moderate to severe filamentous fungal ulcers. Studies consistently suggest that voriconazole has a limited role in the treatment of filamentous fungal ulcers.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Narayana S, Krishnan T, Ramakrishnan S, et al. Mycotic Antimicrobial Localized Injection: A Randomized Clinical Trial Evaluating Intrastromal Injection of Voriconazole. Ophthalmology. 2019. PMID: 30904540. doi:10.1016/j.ophtha.2019.03.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。